Health Project

Location:

West Hartford, CT, 06107

Posted:

December 02, 2012

Contact this candidate

Resume:

CURRICULUM VITAE

Peng Liu, Ph.D., M.D.

Home address:

** **** ******** *****

West Hartford, CT 06107

Cell: 1-500-***-**** in China

Email: ***********@*****.***

Educations:

| | | |) | |

|Beijing Medical |M.S. | |1990 |Immunology |

|Suzhou Medical College, |M.D. | |1985 |Medicine |

Employments

|09/2009- |Professor of Skeletal Development and Regenerative medicine, |

| |Wuhan University School of Dentistry |

|1/07-5/09 |Principal Investigator/Associate Professor, Maine Institute for|

| |Human Genetics and Health, Brewer, ME; Adjunct Research |

| |Scientist, The Jackson Laboratory, Bar Harbor, ME. |

|7/2005-12/06 |Team Leader/Senior Scientist, Stem Cell Biology, Aastrom |

| |Biosciences, Inc., Ann Arbor, MI. |

|11/2005 to |Adjunct Research Scientist (adjunct faculty appointment |

|12/2006 |equivalent to Assistant Professor), Dept. of Biologic and |

| |Materials Sciences, University of Michigan School of Dentistry,|

| |Ann Arbor, MI |

|10/2001-7/200|Instructor, Dept. of Genetics and Developmental Biology, |

|5 |University of Connecticut Health Center (UCHC), CT. |

|1997-10/2001 |Postdoctoral Fellow, Dept. of Genetics and Developmental |

| |Biology, University of Connecticut Health Center, CT. |

|1993-1997 |Research Student, Dept. of Human Metabolism and Clinical |

| |Biochemistry, University of Sheffield Medical School, |

| |Sheffield, England. |

|1990-1993 |Assistant Professor, Dept. of Bone Metabolism and Nuclear |

| |Medicine, China-Japan Friendship Hospital, Beijing, China. |

|1985-1986 |Editorial Department for Chinese Journal of Radiobiology and |

| |Radiation Protection, Chinese Association of Medicine, Ministry|

| |of Public Health, China. |

Research Experiences:

09/2009- Principal investigator, the Key Lab of Oral Diseases, Wuhan

University Dental School. My Research focuses on the role of

Notch/Wnt signalling pathway in regulating bone cell

differentiation using and making several transgenic and knockout

mouse models.

1/2007-5/08: Principal Investigator/Research Scientist, Maine Institute

for Human Genetics and Health. Develop a bone research program

working on Notch signalling pathway in regulation of bone cells

and microRNA in bone cell biology. My laboratory was located in

The Jackson Laboratory, Bar Harbor, Maine.

7/2005-12/2006: Team Leader, Stem Cell Biology, Aastrom Biosciences, Inc.,

Ann Arbor-based stem cell therapeutic company. Report to Vice

President Global Research and Chief Scientific Officer, Aastrom

Biosciences, Inc.

1) Provided key data to define the multipotent nature of Aastrom's

autologous bone marrow-derived Tissue Repair Cells, to support

their use in multiple clinical applications, including

orthopaedics, vascular disease and cardiovascular disease.

Developed novel technology using GFP-lentivirus transduction to

target key bone cell promoter to demonstrate directly that stem

cells contribute to differentiated cell populations in vivo; my

team scientist was awarded 2006 ASBMR Young Investigator Award

for aspects of this research. Established molecular

biology/recombinant DNA and animal research capabilities for the

company. Identified a key manufacturing problem in processing

TRC that affected the quality of the final cell product.

2) Created and implemented technological capabilities in histology,

especially frozen sections of bone and use of confocal

microscopy; in molecular/virus core; and in animal models for

bone regeneration. To accomplish this, I worked in close

collaboration with scientists at the University of Michigan so

they allowed us to use their animal, histology and molecular

imaging facilities, participated in a series of seminars.

Assistance with scientists in UM for utilizing GFP marking stem

cells, evaluating bone phenotype of transgenic mice and

culturing human bone marrow cells.

3) Develop three projects: Further characterize the company's

'Tissue Repair Cell' Product'; Using GFP and other molecular

imaging technology to track the fate of human bone marrow stem

cells to multiple lineage including osteoblasts, endothelial

cells and neural cells and to determine the contribution of

grafted human stem and progenitor cells to tissue regeneration

using several animal models. These works support the company's

clinical claims and application to FDA approval for marketing

the products; Obtained solid data to extend its pending patents.

4) Submit 4 NIH SBIR grant proposals in FY06 - 2 were scored and I

will resubmit. Two manuscripts in preparation,

5) Established strong academic collaborations with experts in the

bone field:

1) With Drs. David Rowe, Alexander Lichtler at University of

Connecticut Health Center: Using GFP technology for

tracking human bone marrow stem cells;

2). With Dr. Joseph Lorenzo at University of Connecticut

Health: Characterization of osteoclast potential in TRC;

3). With Drs. Paul Krebsach, William Giannobile and Peter Ma

at University of Michigan School of Dentistry: Evaluating

bone formation potential of TRC and interaction with

biomaterials; Submitted SBIR grants.

4). With Drs. Fangyu Peng and O. Muzik at Wayne State

University Medical School: Develop an in vivo molecular

imaging strategy using hCtr1 reporter for tracking human

stem cells for bone regeneration; submitted a SBIR grant.

5). With Dr. Grigori Enikolopov at Cold Spring Harbor

Laboratory: Using a neural specific promoter driven GFP

for tracking the fate of TRC into neural lineage.

6). With Dr. James Richard Spears at Wayne State University

Medical School: Submitted a Michigan Life Science Grant

for development of adult stem cells for myocardial repair.

(5). Supervision experience: Management of one scientist and two

research associates. I mentored a team scientist, Dr. Dezhong

Yin, was awarded an ASBMR Young Investigator Award at the 2006

28th ASBMR Annual Meeting, for an oral presentation entitled

'Efficient Tracking of the Fate of Human Bone Marrow Stem Cells

for Bone Regeneration Using a Bone Specific Promoter Driving GFP

Within a Lentiviral Vector'.

2001-7/2005: Instructor, Dept. of Genetics and Developmental Biology,

University of Connecticut Health Center, CT, USA. I contributed

to planning, designing, executing the following in vivo and in

vitro research in collaboration with my mentors, Drs. David Rowe

and Dan Wu:

1) Wnt Project: In collaboration with Prof. Dan Wu, a leading

expert of the Wnt signalling transduction, UCHC, we investigated

the role of the Wnt signalling pathway, particularly DDK2 and

Wnt7B, on bone formation in vitro and in vivo by characterizing

DKK2 KO mice. My major role of this project was to lead 2 post-

docs in performing in vivo and in vitro characterization of DKK2

knockout mice (bone marrow stromal cell culture, bone mass

measurement by DEXA, CT, pQCT, histology, and

histomorphometry). In addition, we identified two small

molecules that bind to the Dkk-binding cavity by a high

innovative approach. The two small molecule compounds can

reverse Dkk-mediated inhibition of the Wnt activity and I

performed in vivo experiments to validate the anabolic effect on

bone formation. Some exciting results were observed. I was also

well trained in histomorphmetry in Dr. Gloria Gronowicz's

laboratory, University of Connecticut Health Center.

Achievements:

. Established a bone research group in Dr. Wu's

laboratory and made a significant contribution to a

RO1 grant founded from NIAMS, NIH in 2005. Supervision

of three postdoctors.

. A high through-put screen to identify small molecules

for enhancing the Wnt activity for bone formation.

. Aspects of the data were orally presented as a late-

breaking abstract at the 2004 25th annual meeting of

ASBMR, the meeting for Advances in Skeletal Anabolic

Agents for the treatment of Osteoporosis, 2004 and at

the 2005 27th ASBMR Annual Meeting.

. Two patents were approved based on the data from the

Wnt/bone project.

. One paper published in Nature Genetics 2005; 37:945-

952.

2) Presenilin-1 (PS1) project: To explore the concept that the

under-performance of a molecular pathway may contribute to the

development of osteoporosis, PS1 heterozygous knockout mice were

used to determine the influence of the Notch/Wnt signalling

pathways on bone formation in postnatal life. The PS1

heterozygous mice had no obvious phenotype by DEXA and CT.

Using a powerful bone promoter-driven GFP marker

(3.6ColGFP/2.3ColGFP), I observed impaired osteoblast lineage

progression in vivo and in vitro. These data were presented as

a plenary poster at the 2003 ASBMR annual meeting. I also

helped supervise a lab technician in characterization of bone-

promoter driven GFP transgenic mice in vivo.

3) Complementary antiRNA Strategies for Osteogenesis Imperfecta

(OI): This project was funded by Osteogenesis Imperfecta

Foundation; I was the principal investigator. Efforts were made

to develop retroviral/adenoviral vectors to deliver the modified

U1snRNA and siRNA for knockdown of a mutation that causes OI. A

lentiviral delivered siRNA successfully reduced a mutant Col1A2

in primary fibroblasts via a 9-fold decrease of the mutant

Col1A2 expression. I made U1anti-target construct functioning

in a N2A retroviral vector and observed a strong reduction of a

targeted gene expression in stable condition. In addition, I

worked on bone marrow cells transplantation in mice and achieved

a successful transplantation of bone promoter driving GFP-

positive cells from donor to recipient mice.

4) The Lineage Progression of Human Osteoprogenitor Cells: Based on

experience obtained from GFP transgenic mice developed in Dr.

Rowe's lab as a powerful tool to define differentiation of the

murine osteoblast lineage, I applied the same GFP transgene

strategy to primary human bone marrow stromal cells (hBMSCs).

Retroviral/lentiviral vectors ware utilized to deliver a variety

of bone active promoter driving GFP markers. FAC sorting was

used to isolate subpopulations at defined stages for subsequent

microarray analysis of the osteoblast differentiation. A R21

grant application was submitted early 2004 in response to NIA

RFA AG-04-009 (Assays of Stem Cell Function in Clinical

Research) to 'assess the lineage progression of human

osteoprogenitor cells' with a score of 190. This strategy could

possibly become a diagnostic tool for patients with premature

osteoporosis by identifying patients' under-performing genes

that are important for the lineage development. With this

information, the clinician could treat patients with a drug that

specifically targets the molecular pathway affected by those

under-performing genes.

1997-2000: Postdoctoral Fellow in Dr. David Rowe's laboratory, Dept.

of Genetics and Developmental Biology, University of Connecticut

Health Center, CT, USA.

1) Transduction of hBMSCs with VSV-pseudotyped retrovectors

encoding target genes, such as GFP and (-Gal; and

characterization of osteogenic differentiation of these

transduced cells.

2) Development and characterisation of the modified human U1

snRNA to inhibit transgenes and endogenous genes at pre-mRNA

level. This approach offers distinct advantages over

antisense and ribozyme approaches.

3) Characterisation of transgenic mice harbouring osteocalcin

promoter driving GFP as a late bone differentiation marker,

in comparison to that of a collagen promoter driven GFPtpz.

1993-1997: Research Student, Dept. of Human Metabolism and Clinical

Chemistry, University of Sheffield. The Major Advisor:

Professor Graham Russell.

1) Investigation of type II collagen degradation in chondrocytes

by SDS-PAGE, Western blot, immunocytochemistry, ELISA;

cultures of bovine chondryoctyes.

2) Examination of the effects of growth factors on osteogenic

differentiation of hBMSCs by biochemistry, RT-PCR, Northern

blots, immunocytochemistry, ELISA.

3) Characterization of cadherins in hBMSCs by biochemistry,

Western blot, immunocytochemistry.

1990-1993: China-Japan Friendship Hospital, Beijing, China. Assistant

Professor, Dept. of Bone Metabolism and Nuclear Medicine.

Appointed as the Director of the Dept. in 1993.

1) Clinical trials of osteoporosis.

2) WHO study of hip fracture and osteoporosis in Beijing. A

project director of bone mass measurement, in collaboration

with Dr. S. Communings, UCSF.

3) Organization of 1st international symposium on osteoporosis,

Beijing, May 8-11, 1992 as the executive secretary of the

organization committee.

1985-1990: Scientist, Lab. of Industrial Hygiene, Ministry of Public

Health, China.

1) Investigation of biologic effects of radiation in vivo and in

vitro.

2) Examination of the biologic effects of mixed rare earth

elements on lung and immune systems of miners and animals.

Professional Activities:

1. Associate Editor, International Journal of Oral and Craniofacial

Tissue Engineering, 03/2010-

2. Committee member, Chinese Society of Oral Biomedicine, from

03/2010-

3. Committee member, Osteoporosis society in Hubei Provence, from

04/2010-

4. Member, American Society for Bone and Mineral Research, from 1993

to present.

5. Member, International Chinese Hard Tissue Society (ICHTS), from

1997 to present.

6. Member, the Board of Directors of ICHTS.

7. Chair, the Membership Committee of ICHTS.

8. The Secretary in General, the Chinese Society of Osteoporosis,

from 1992 to 1993.

9. The Executive Secretary of the First International Symposium of

Osteoporosis, Beijing, 1992.

Honours:

1) University Graduate Scholarship, University of Sheffield, England

(1993 to 1997).

2) Suzhou Medical College Scholarship for Outstanding Student, China

(1981 to 1985).

Peer- Review Grant Reviews:

1. The American Institute of Biological Sciences (AIBS) and the

United States Army Research and Materiel Command (USAMRMC), serve

as a reviewer on Panel C-Two: Osteoporosis & Bone Related Disease,

March 2004.

2. Division of Basic Research in Clinical Medicine, Dept. of Life

Science, the National Natural Science Foundation of China (NSFC),

April, 2004 and 2005.

National and regional Symposium organizer:

1. Organizer, the international osteoporosis workshop, Dec., 1992,

Beijing, China.

2. Executive Secretary, the First International Symposium on

Osteoporosis, Beijing, May 8-11, 1992.

3. Member of organization committee, the International Conference on

Osteoporosis and Bone Mineral Research, Oct. 10-14, 2003, Beijing,

China.

4. Local Organizer, the annual leadership meeting for international

Chinese Hard Tissue Society, June 12-13, 2004 at Yale, New Haven,

Connecticut.

5. The member of organization committee and chair a section, the second

International Conference on Osteoporosis and Bone Research (ICOBR) is

to be held on Oct 19-23, 2005, Chengdu, China.

Publications.

Peng LIU, Zhipeng FAN, Songlin WANG?Understanding of stem cells in

bone biology and translation into clinical applications. Frontier in

Biology 2010 5: 5: 386-395.

Yin D, Wang Z, Gao Q, Sundaresan R, Parrish C, Yang Q, Krebsbach PH,

Lichtler AC, Rowe DW, Hock J, Liu P. Determination of the Fate and

Contribution of Ex Vivo Expanded Human Bone Marrow Stem and

Progenitor Cells for Bone Formation by 2.3ColGFP. Mol Ther. 2009 Jul

14. [Epub ahead of print]

Liping Xiao, Peng Liu, Xiaofeng Li, Takahiro Naganawa, Thomas

Doetschman, J. Douglas Coffin, Marja M. Hurley. The exported 18kDa

isoform of FGF-2 is a critical determinant of bone mass in mice. J

Biol Chem. 2009 Jan 30;284(5):3170-82

Li, X.*, P. Liu*, Liu,W.; Maye,P.; Zhang,J.; Zhang,Y.; Hurley,M.;

Guo,C.; Boskey,A.; Sun,L.; Harris,S.E.; Rowe,D.W.; Ke,H.Z.; Wu,D.

Dkk2 has a role in terminal osteoblast differentiation and

mineralized matrix formation. Nat Genet. 2005;37:945-952. (* Equal

contribution to this work).

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D.

(2005): Sclerostin binds to LRP5/6 and antagonizes canonical Wnt

signaling. J Biol Chem 2005;280:198**-*****.

Liu, P, Lin JH, Zhang B. Differential regulation of cadherin

expression by osteotropic hormones and growth factors in vitro in

human osteoprogenitor cells. Acta Pharmacol Sin. 2005;26:705-713.

Liu, P. Stover ML, Lichtler A, Rowe DW. (2005): Modification of human

U1snRNA for inhibiting of targeted gene expression at Pre-mRNA level,

Methods Mol Biol. 309:321-332

Liu, P., Kronenberg, M. Jing, X. and D. W., Rowe (2004). Modified U1

snRNA suppresses expression of a targeted endogenous RNA by

inhibiting polyadenylation of the transcript, Nucleic Acids Research

32 (4): 1512-1517.

Fortes, P., Cuevas, Y., Guan, F., Liu, P., Pentlicky, S., Jung, S.P.,

Martinez-Chantar, M.L., Prieto, J., Rowe, D. and Gunderson, S.I.

(2003). Inhibiting expression of specific genes in mammalian cells

with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons

of pre-mRNA. Proc Natl Acad Sci U S A..

Xiao, L., Liu, P., T. Sobue, A. Lichtler, J.D. Coffin, and M.M.

Hurley (2003). Effect of overexpressing fibroblast growth factor 2

protein isoforms in osteoblastic ROS 17/2.8 cells. J Cell Biochem.

89:1291-301.

Kalajzic, Z., Liu, P., Kalajzic, I., Du, Z., Braut, A., Mina, M.,

Canalis, E., and D. W. Rowe (2002). Directing the expression of a GFP

transgene in differentiated osteoblasts: A comparison between

collagen and osteocalcin promoters. Bone 31 (6): 654-660.

Liu, P., Gucwa, A., Stover, M.L., Emily Buck, E., Lichtler, A. and

Rowe, D. W. Rowe (2002). Analysis of Inhibitory Action of Modified

U1 snRNAs on Target Gene Expression: Discrimination of two RNA

targets differing by a 1 bp mismatch. Nucleic Acids Research 30 (11):

2348-2358.

Liu, P., Kalajzic, I., Stover, M. L., Rowe, D. W., and Lichtler, A.

C. (2001). Human bone marrow stromal cells are efficiently

transduced by vesicular stomatitis virus-pseudotyped retrovectors

without affecting subsequent osteoblastic differentiation. Bone

29(4): 331-5

Kalajzic, I., Stover, M. L., Liu, P., Kalajzic, Z., Rowe, D. W., and

Lichtler, A. C. (2001). Use of VSV-G pseudotyped retroviral vectors

to target murine osteoprogenitor cells. Virology 284(1):37-45.

Beckley, S. A., Liu, P., Stover, M. L., Gunderson, S. I., Lichtler,

A. C., and Rowe, D. W. (2001). Reduction of target gene expression

by a modified U1 snRNA. Mol Cell Biol 21(8): 2815-25.

Liu, P., Babatunde O. Oyajobi, R. Graham G. Russell and Andrew Scutt

(1999). Regulation of Osteogenic Differentiation of Human Bone

Marrow Stromal Cells: Interaction Between TGF-( and 1,25(OH)2D3 in

vitro. Calcif. Tissue Int. 65: 173-180.

K. Donson, S. Jones, Liu, P., D. Miao, L. Reading, C. Shui, K. Still,

A. Scutt (1998). The Advantages and Limitations of Cell Culture as a

Model of Bone Formation. Ernst Schering Research Foundation Workship

25.

Liu, P., Xian Chen (1993). Effects of Rare Earth Nitrates on the

Immune Functions of Mice. Journal of Chinese Rare Earth Society, 11

(4): 349-352.

Abstracts:

D. Yin*1, Z. Wang*2, Q. Gao*2, R. Sundaresan*1, P. H. Krebsbach*2, A.

Lichtler3, D. W. Rowe3, J. M. Hock1, P. Liu1 (2006). Efficient

Tracking of the Fate of Human Bone Marrow Stem Cells for Bone

Regeneration Using a Bone-Specific Promoter Driving GFP within a

Lentiviral Vector. It will be at ASBMR 28th Annual Meeting in

Philadelphia, PA, Sept. 15-19, 2006.

P. Liu, Y. Zhang, X. Li, J. Zheng, D. Wu. (Year?) Enhancement of

Bone Formation by Small Molecule Compounds that Disrupt Dkk-LRP5/6

Interaction, Journal of Bone and Mineral Research (2205, Suppl1):

1062.

P. Liu, X. Jiang*, L. Wang*, D. Rowe (2003). Abnormalities of

Osteoblast Lineage Differentiation in Presenilin Heterozygous

Knockout Mice. Journal of Bone and Mineral Research 18 (suppl 2):

F215.

P. Liu, M. Stover*, A. Lichtler, D. Rowe (2003). Isolation of

Differentiated Osteoblasts from Human Bone Marrow Stromal Cells Based

on Expression of a Retroviral Delivered Col2.3GFP Transgene. Journal

of Bone and Mineral Research 18 (suppl 2): M215.

L. Wang*, Y. Liu*, X. Jiang*, P. Liu, D. Rowe (2003). Acute Response

of Resident Osteoblasts to Total Bone Marrow Ablation. Journal of

Bone and Mineral Research 18 (suppl 2): M175.

L. Xiao, P. Liu, T. Sobue, J. Coffin, M. M. Hurley (2002).

Overexpression of FGF2 Protein Isoforms in Osteoblasts: Effects on

Proliferation and Differentiation. Journal of Bone and Mineral

Research 17 (suppl 1): M1127.

P. Liu*, M. S. Kronenberg*, D. W. Rowe* (2001) Inhibition of

Expression of Endogenous Genes Within Cells of the Osteoprogenitor

Lineage. Journal of Bone and Mineral Research 16 (suppl 1): M054.

Z. Kalajzic1, P. Liu*1, I. Kalajzic*2, Z. Du*3, A. Braut4, E.

Canalis*3, R. Derynck*5, M. Mina*4, D. W. Rowe*1 (2001). Analysis of

an Osteocalcin GFP Reporter Transgene in Transgenic Mice. Journal of

Bone and Mineral Research 16 (suppl 1): SU237.

P. Liu, M. L. Stover, A. Beckley, S. Gunderson, D. Rowe (1999): A

modified human U1 gene inhibits target gene expression by a mechanism

that depends on base-pairing specificity. Journal of Bone and

Mineral Research 14 (suppl. 1): SU097.

P. Liu, I. Kalajzic, M.L. Stover, D. Rowe, A. Lichtler (1998): Human

bone marrow stromal cells are targeted by VSV psuedotyped

retrovectors. Bone 23 (5): SA378.

I. Kalajzic, D. Visnjic, P. Liu, M. L. Stover, M. Hurley, D. Rowe, A.

Lichtler (1998): Use of VSV pseudotyped retrovectors to target murine

osteoprogenitor cells. Bone 23 (5): SA018.

X.S. Cao, A. Houghton, P. Liu, R.G.G. Russell, and B.M.J. Stringer

(1997): Characterization of an Immortalized Human Foetal Chondrocyte

Cell Line, HFFCL3, with a Hypertrophic Phenotype. Bone 20 (4S):

P239.

P. Liu, B. Oyajobi, RGG Russell (1995): Regulation of Differentiation

of Human Bone Marrow Stromal Cells into Osteoblast-like Cells by TGF-

( and 1,25D3. Autumn meeting of bone and tooth society, U.K., Sept.

28-29, 1995, P50.

B.O. Oyajobi, A. Houghton, P. Liu, H. Hasan, B.M. J. Stringer and

R.G.G. Russell (1995): Interleukin 11 (IL-11) and Transforming Growth

Factor-beta(TGF- but not Interleukin 4 (IL-4) Inhibit Interleukin 6

(IL-6) Produced by Immortalized Human Bone Marrow Stromal Cells.

Bone, 17(6):570.

Oral presentation:

P. Liu, Y. Zhang, X. Li, J. Zheng, D. Wu (2005): Enhancement of Bone

Formation by Small Molecule Compounds that Disrupt Dkk-LRP5/6

Interaction. Concurrent Oral Presentatiom (1062), 27th Annual

Meeting of ASBMR, Sept. 21-26,2005, Nashville, TN

P. Liu, X. Jiang and D.W. Rowe (2003): Abnormalities of Osteoblast

Lineage Differentiation in Presenilin-1 Heterozygous Knockout Mice.

The International Conference on Osteoporosis and Bone Mineral

Research, Oct. 10-14, 2003, Beijing, China.

X. Li, P. Liu, J. Zhang. Y. Zhong. S. Harris, D. Rowe, D. Wu (2003):

Dkk2 is Upregualted by Canonical Wnt and Stimulates Osteoblast

Mineralization at the Late-Breaking Abstract Session of the 25th

Annual Meeting of ASBMR (the first co-author of this work).

P. Liu, M. L. Stover, A. Beckley, S. Gunderson, D. Rowe (1999): A

modified human U1 gene inhibits target gene expression by a mechanism

that depends on base-pairing specificity. 19th Annual Meeting, East

Cost Connective Tissue Society.

Research Funding During the Last Three Years:

1. Complementation of AntiRNA Vectors for OI

PI: Peng Liu, Dates: 10/1/03-9/31/05

Agency: Osteogenesis Imperfecta Foundation Type: Clinical Seed

Grant, $120,000

This grant will apply modified U1snRNA and widely used RNAi

technologies to knock down mutations that cause OI disease.

2. The Wnt Signaling Transduction in Bone Biology.

Co-Investigator: Peng Liu, 25% efforts (PI: Dan Wu) Dates:

4/1/2005-3/31/2010.

Agency: NIH/NIAMS Type: R01

This grant application answers the call for research proposals (PA-

03-008) to study the relationship between LRP5/DKK and bone mass.

3. Aastrom Biosciences Inc. Internal funding for my program. 2005-

present

Patents

United States Patent 200********: Composition and methods for the

stimulation or enhancement of bone formation and the self-renewal of

cells, filed on May 24, 2004. Role: Co-Inventor.

United States Patent 200********: 'Composition and methods for bone

formation and remodelling, filed on May 24, 2004. Role: Co-Inventor.

Three professional references:

David W. Rowe, M.D.

Director and Professor,

Center for Regenerative Medicine and

Skeletal Development

Department of Reconstructive Sciences

School of Dental Medicine

University of Connecticut Health Center

263 Farmington Avenue

Farmington, CT 06030

Phone: 860-***-****

Fax: 860-***-****

Email: ****@******.****.***

Alexander Lichtler, Ph.D.

Associate Professor,

Center for Regenerative Medicine and

Skeletal Development

Department of Reconstructive Sciences

School of Dental Medicine

University of Connecticut Health Center

263 Farmington Avenue

Farmington, CT 06030

Phone: 860-***-****

Fax: 860-***-****

Email: ********@******.****.***

Bo Chang, M.D.

Research Scientist

The Jackson Laboratory

600 Main Street

Bar Harbor, Maine 04609

Email: **.*****@***.***

Phone: 207-***-****

Contact this candidate